“A Perfect Strategic Fit,” Says Thermo Fisher CEO
“Clario is an outstanding strategic fit, enabling faster, more informed drug development through differentiated technology and data intelligence,” said Marc N. Casper, Thermo Fisher’s chair, president, and CEO.
Casper added that the acquisition reflects the company’s disciplined capital deployment strategy, which has consistently created shareholder value. By combining Thermo Fisher’s world-class laboratory services with Clario’s advanced data ecosystem, the deal will enhance AI use across clinical trials, boost analytical efficiency, and drive innovation in the biotech and pharmaceutical sectors.
Financial and Legal Details
The transaction—expected to close by mid-2026, pending regulatory approval and customary conditions—will be funded through a mix of debt financing and cash reserves. Thermo Fisher anticipates the deal will deliver a double-digit internal rate of return and be immediately accretive to its adjusted operating margins.
Clario will join Thermo Fisher’s Laboratory Products and Biopharma Services segment following the close.
WilmerHale is serving as lead deal counsel to Thermo Fisher, with Axinn Veltrop & Harkrider LLP and Freshfields LLP handling regulatory aspects. Latham & Watkins LLP represents Clario and its sellers.
The WilmerHale team is led by partners Hal Leibowitz and Andrew Bonnes. Details on other counsel teams were not immediately available.
